+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

This research aims to evaluate the effectiveness of an evidence-based approach called Screening, Brief Intervention, and Referral to Treatment SBIRT among adult patients who screen positive for risky alcohol or substance use behaviors while seeking care at sexual and reproductive health clinics. The study focuses on whether SBIRT can improve patients alcohol and substance use, sexual and reproductive health, mental and physical health, quality of life, and wellbeing. It also explores if SBIRTs impact varies by ethnicity, socioeconomic status, age, gender, urbanicity, and delivery mode in-person vs. telemedicine. Participants are randomly assigned to receive either the SBIRT intervention delivered both in-person and via telemedicine or usual care, which lacks a standardized screening or treatment approach. The SBIRT intervention includes validated screening tools, brief motivational interviewing-based interventions lasting 5 to 10 minutes, and referrals to specialty addiction treatment for severe cases. The study is conducted within a large family planning clinic network serving a diverse population of reproductive-aged individuals. During the study, participants complete surveys and interviews at baseline, 30 days, and 3 months to assess various outcomes such as alcohol and drug use frequency, sexual behaviors under influence, mental health status, and wellbeing. Researchers also monitor the implementation and use of SBIRT by clinics and providers over a 12-month period. The trial aims to provide guidance on scaling integrated alcohol and substance use services in sexual and reproductive health settings, promoting health equity among reproductive-aged populations.

Age: 18Years +All GendersPhase Not Applicable
4 locations
S

Actively Recruiting

Researchers are evaluating a new digital avatar-guided support program designed to help emerging adults aged 18 to 29 who visit the emergency department with suicidal thoughts and alcohol misuse. The study aims to understand if participants use and find the program helpful, whether they can complete daily surveys for 28 days and follow-up surveys over 12 weeks, and if the program shows early signs of reducing alcohol use and suicidal thoughts. The study compares this new program to a freely available suicide safety planning app. Participants will be randomly assigned to one of two groups. One group will use the avatar-guided digital intervention with text message reminders, which includes monitoring alcohol use and suicidal triggers, skills training, resources for outpatient care and crisis hotlines, and milestone achievements. The other group will use a free suicide safety planning app that helps create a personalized safety plan. All participants receive standard emergency department care and any follow-up or referral services needed. During the study, participants will complete surveys at the start and at 4, 8, and 12 weeks, along with daily short surveys for 28 days. Researchers will assess alcohol use, suicidal thoughts, and related experiences, as well as participant satisfaction and safety through adverse event monitoring. The total participation lasts 12 weeks, focusing on acceptability, feasibility, and early signals of the programs effects.

Age: 18Years - 29YearsAll GendersPhase Not Applicable
2 locations
E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and immune response of an Acne mRNA vaccine in adults aged 18 to 45 years with moderate to severe acne. This Phase III study is the first to test this vaccine in humans and aims to find the best dose to use in future larger trials. Acne is a common inflammatory skin condition that affects millions worldwide, and current treatments have not changed much over the past 30 years. This study is sponsored by Sanofi Pasteur, a Sanofi Company. The trial includes up to three intramuscular injections of the Acne mRNA vaccine at different dose levels. Participants are divided into four groups two groups receive two injections and two groups receive three injections. Each vaccination group has a matching placebo group for comparison. The Core Study includes Sentinel and Main cohorts for both the two- and three-dose regimens. After completing the Core Study, some participants will enter a long-term follow-up period lasting up to 30 months to assess lasting effects of the vaccine. One group will be invited to join a separate long-term extension study. During the study, participants will be closely monitored for side effects shortly after each injection and for several months thereafter. Researchers will measure changes in the number of acne lesions and immune responses through blood tests. Safety assessments include tracking any adverse events and laboratory test results. Visits will include medical evaluations and questionnaires. The total participation time may extend beyond the Core Study to include long-term follow-up for some participants, lasting up to 38 to 40 months after the first injection.

Age: 18Years - 45YearsAll GendersPhase 1Phase 2
94 locations